| 申思思,潘浩,许轶洲,蔡丽丽.比索洛尔联合曲美他嗪治疗射血分数保留型心力衰竭的临床疗效及预后分析[J].浙江中西医结合杂志,2022,32(3): |
| 比索洛尔联合曲美他嗪治疗射血分数保留型心力衰竭的临床疗效及预后分析 |
| Clinical efficacy and prognosis of bisoprolol combined with trimetazidine in the treatment of heart failure with preserved ejection fraction |
| 投稿时间：2021-08-31 修订日期：2021-12-23 |
| DOI： |
| 中文关键词: HFpEF 比索洛尔 曲美他嗪 联合治疗 |
| 英文关键词:HFpEF Bisoprolol Trimetazidine Combination therapy |
| 基金项目: |
|
| 摘要点击次数: 745 |
| 全文下载次数: 14 |
| 中文摘要: |
| 目的：分析比索洛尔辅助曲美他嗪治疗射血分数保留型心力衰竭(HFpEF)的临床疗效,及对预后的影响。方法：96例HFpEF患者根据具体治疗方法分为对照组和观察组；对比临床效果以及相关指标水平。结果：观察组有效率较对照组显著升高(χ2 =6.839),其代谢当量与ST段下降总和(F=10.407,101.677)、6分钟步行距离(F=27.636)、NT-proBNP(F=52.548)以及心功能指标等改善程度均显著优于对照组。两组药物不良反应无显著差异(2.08% VS 4.17%)；且主要终点事件发生情况分布存在显著差异(Log Rank =4.664)。结论：比索洛尔联合曲美他嗪治疗可显著改善HFpEF患者心功能相关指标,是一种安全有效的治疗方案。 |
| 英文摘要: |
| [Objective] To analyze the efficacy of bisoprolol-assisted trimetazidine in the treatment of heart failure with preserved ejection fraction, and its effect on the prognosis. [Methods]96 HFPEF patients were divided into control group and observation group, the clinical effect and related indicators were compared.[Results]The effective rate of the treatment in observation group was significantly higher thanthe control group(χ2=6.839).The improvement of metabolic equivalent and ST segment decline(F=10.407,101.677), 6-minute walking distance (F=27.636), NT-proBNP(F=52.548) and cardiac function indexin the observation group were better. And there was no significant difference in adverse drug reactions between the two groups(2.08% VS 4.17%). The distribution of primary endpoint events was significantly different between the two groups (Log Rank =4.664). Conclusion:Bisoprolol combined with trimetazidine can significantly improve cardiac function in patients with HFPEF, and is a safe and effective treatment program. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
